Ibuprofen business continues to drag profitability
Ibuprofen recorded negative EBITDA again; strategic options may not yield favorable outcome, prolonging losses.
high · management_commentarySolara Active Pharma Sciences Limited — Q4 FY26
Solara delivered its strongest quarter in eight quarters, with revenue of ₹392 crore (up 12% QoQ) and EBITDA of ₹61 crore (up 65% QoQ), driven by the base business which operate...
bullish
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
R&D spend not yielding near-term results
Despite ₹200 crore R&D spend over 4-5 years, no new profitable product launched; new DMFs will only commercialize from FY29.
medium · management_commentaryVizag facility mothballed with ongoing costs
Vizag site mothballed since 2024 incurs ₹12-15 crore annual maintenance cost with no revenue.
medium · analyst_questionCustomer concentration in base business
Top 15-20 products contribute 75-80% of base business revenue; loss of any key customer could impact performance.
medium · data_observation